Pfizer amps up push into obesity treatments with $4.9B deal for Metsera
Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5-billion acquisition. The COVID-19 vaccine maker said Monday that it will pay $47.50 in cash for each share of development-stage drugmaker Metsera.
← Back to stories
National5 articles from 5 sources across the spectrum· Updated 373d ago
3 across the spectrum · tap a section to jump
How each side is putting it
Left
1 viewpointPfizer amps up push into obesity treatments with $4.9 billion deal for Metsera
Center
2 viewpointsRan by 3 outlets· WDIO Duluth, WHEC Rochester, +1 more
Right
0 viewpointsNo Right coverage yet.
A blind spot on this side of the story.